Merck KGaA (MRK) Given a €115.00 Price Target at UBS Group

Share on StockTwits

Merck KGaA (FRA:MRK) received a €115.00 ($133.72) target price from stock analysts at UBS Group in a research note issued on Thursday, www.boersen-zeitung.de reports. The firm presently has a “buy” rating on the healthcare company’s stock. UBS Group’s price target suggests a potential upside of 23.36% from the company’s current price.

A number of other equities analysts also recently commented on the stock. Nord/LB set a €80.00 ($93.02) target price on shares of Merck KGaA and gave the stock a “sell” rating in a research note on Thursday, January 24th. Goldman Sachs Group set a €95.00 ($110.47) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, February 12th. Credit Suisse Group set a €110.00 ($127.91) target price on shares of Merck KGaA and gave the stock a “buy” rating in a research note on Thursday, November 15th. JPMorgan Chase & Co. set a €100.00 ($116.28) target price on shares of Merck KGaA and gave the stock a “neutral” rating in a research note on Tuesday, January 8th. Finally, Oddo Bhf set a €100.00 ($116.28) price target on shares of Merck KGaA and gave the company a “neutral” rating in a research report on Wednesday, November 14th. Two equities research analysts have rated the stock with a sell rating, twelve have given a hold rating and seven have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of €98.90 ($115.00).

Shares of MRK stock opened at €93.22 ($108.40) on Thursday. Merck KGaA has a 12 month low of €76.60 ($89.07) and a 12 month high of €115.00 ($133.72).

Merck KGaA Company Profile

MERCK Kommanditgesellschaft auf Aktien operates in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat infertility, growth hormone deficiencies, type 2 diabetes, cardiovascular and thyroid diseases, multiple sclerosis, and colorectal cancer, as well as carcinoma of the head and neck; diagnostics and prescription drugs for allergen immunotherapy; and fertility treatments.

Recommended Story: Swap

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Tesla Inc  Shares Bought by Apriem Advisors
Tesla Inc Shares Bought by Apriem Advisors
Amundi Pioneer Asset Management Inc. Sells 109,849 Shares of Gaming and Leisure Properties Inc
Amundi Pioneer Asset Management Inc. Sells 109,849 Shares of Gaming and Leisure Properties Inc
American National Bank Lowers Stake in Procter & Gamble Co
American National Bank Lowers Stake in Procter & Gamble Co
American International Group Inc. Lowers Position in Ingevity Corp
American International Group Inc. Lowers Position in Ingevity Corp
American International Group Inc. Sells 348 Shares of Spirit Airlines Incorporated
American International Group Inc. Sells 348 Shares of Spirit Airlines Incorporated
Clorox Co  Shares Bought by Apriem Advisors
Clorox Co Shares Bought by Apriem Advisors


© 2006-2019 Ticker Report